curasan AG: Bioactive Bone Regeneration Material Approved for Sale in Europe
curasan AG has received European approval for its new granular bone regeneration material Ceracell®
Kleinostheim, Germany, October 23, 2010 --(PR.com)-- curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell®.
Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell® in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approximately three months later in the orthopaedic market.”
Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration. Ceracell® is especially suitable when the body’s own healing potency needs to be reinforced by substances for bone growth such as PRP, BMP, bone marrow or stem cells.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell® in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approximately three months later in the orthopaedic market.”
Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration. Ceracell® is especially suitable when the body’s own healing potency needs to be reinforced by substances for bone growth such as PRP, BMP, bone marrow or stem cells.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories